louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03273218: Effectiveness of the Tiger Catheter on Transradial Coronariography: Randomized Compared to JudKins cathETers
Official title: Effectiveness of the Tiger Catheter as a Simple Multipurpuse Catheter in Transradial Coronariography: Randomized Comparerd to Judkins Catheters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Coronary Syndrome
Keywords: coronary angiography
diagnosctic transradial catheter
transradial catheter
Lead sponsor: Hospital San Roque
Sponsor class: OTHER
First posted: 2017-09-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study was to assess effectiveness and safety of Tiger (5Fr) vs Judkins (5Fr) catheters, in coronariography via the right transradial approach.

This was a prospective, randomized, study of paralled design. Consecutive patients with acute coronary syndrome (ACS), eligible for coronary angiography, was randomized after successuful cannulation of right artery and informed consent to either Tiger or Judkins catheters.

Detailed description: analyzed a total of 120 consective diagnostic coronary angioggraphy cases from the right radial approach. Of these 60 cases were performed with single catheter (Tiger) and 60 cases were performed with conventional catheters (Judkins). The patients of both group were overall well balanced for gender, age, risk factors, height, weight and body surface area. Diagnostic angiograms were successfully achieved in all cases via the radial approach.

Eligibility criteria: Inclusion Criteria:

* written informed consent
* indication for coronary angiography

Exclusion Criteria:

* negative Allen´s test
* Chronic renal failure (to preserve the right radial artery for potencial arteriovenous shunting)
* Hemodynamic instability
* coronary artery bypass grafting

Primary outcomes:
measure: Produce time for the coronary angiography
timeFrame: Day 0 (corresponding to time point of produce) assessed by intention - to - tresat analysis (IIT)
Secondary outcomes:
measure: Fluoroscopy time
timeFrame: Day 0 (corresponding to time point of produce)
measure: Contrast Volume used
timeFrame: Day 0 (corresponding to time point of produce)
measure: Radial artery Spasm
timeFrame: Day 0 (corresponding to time point of produce). The radial artery spasm was recorded like YES or NOT.(registry did by nurse from beginning to end of coronary angiography)
Other outcomes:
Locations:
city: Cordoba
country: Argentina
facility: Hospital San Roque
Study officials:
affiliation: Hospital San Roque
name: Marcelo OLIVA, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01799018: Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage
Official title: Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage
Cerebral Vasospasm
Hydrocephalus
Keywords: Xanthine Oxidase
Cerebrospinal fluid
Lead sponsor: State University of New York - Upstate Medical University
Sponsor class: OTHER
First posted: 2013-02-26
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to University Hospital.

Brief summary: The purpose of this study is to determine the role of Proteomics and Metallomics in Cerebral Vasospasm following Subarachnoid Hemorrhage


Eligibility criteria: Inclusion Criteria:

* Non traumatic SAH documented by CT scan
* Patient with SAH who would need external ventricular drain (EVD) for the management of hydrocephalus
* Patients with normal pressure Hydrocephalus that require an external drain
* Control (non - hemorrhagic) group - CSF collected from patients with posterior fossa tumor or stroke with EVD in place for the management of hydrocephalus.

Exclusion Criteria:

* Recent infection within last 1 month of presentation- can increase inflammatory markers
* Recent surgery or acute myocardial infarction within last 1 month of presentation
* Age \> 89 years or \< 18 years

Primary outcomes:
measure: Protein identification and concentration
timeFrame: For the duration of CSF drainage, or until the 21st day after admission.
measure: Metal ion identification and concentration
timeFrame: For the duration of CSF drainage, or until the 21st day after admission.
Secondary outcomes:
Other outcomes:
Locations:
city: Syracuse
country: United States
facility: State University of New York Upstate Medical University
state: New York
Study officials:
affiliation: SUNY Upstate Medical University - Neurosurgery
name: Eric M Deshaies, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05082818: Outcome of Treating Bladder Cancer in Sohag University Hospital
Official title: Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bladder Cancer
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-10-19
Enrollment: 168
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Bladder cancer patients of both sex and aged from 18 to 80 years old

Brief summary: Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020

Detailed description: This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer

Eligibility criteria: Inclusion Criteria:

* all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer

Exclusion Criteria:

* presence of other malignancies

Primary outcomes:
measure: Disease free survival
timeFrame: 2 weeks after treatment to the time of relapse
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
affiliation: Sohag University
name: Samah Refaat
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06813118: Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case
Official title: A RCT Comparing the Effectiveness of a Combination Therapy of Lezra and Clomid Versus Lezra Alone for Inducing Ovulation in Women Diagnosed With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Polycystic Ovarian Syndrome
Lead sponsor: HITEC-Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2025-02-06
Enrollment: 42
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomization intervention RCT
Primary purpose: TREATMENT

Brief summary: Clomiphene citrate resistant i.e failure to ovulate after 6 cycles of ovulation induction effects 15-40% of patients with PCOS.Two treatment groups will be formed one recieving letrozole alone and another recieving CC and letrozole combined.Mature follicles and endometrial thickness will be checked by transvaginal ultrasound and results will be recorded.

Detailed description: Subfertility is characterized by the inability to achieve conception despite engaging in regular unprotected sexual intercourse for 1-2 years.PCOS exhibits chacteristic traits such as obesity,heightened insulin resistance accompanied by compensatory hyperinsulinemia,oligo/anovulation and subfertility.Clompiphene citrate induces ovarian stimulation.Letrozole ,an aromatase inhibitor emerges as a novel medication with comparable efficacy to CC as a first line treatment for inducing ovulation in cases of anovulation.

Eligibility criteria: Inclusion Criteria:

* women of 20-40 years with a history of PCOS and resistant to CC

Exclusion Criteria:

* Premature ovarian insufficiency
* Husband has oligo azoospermia
* Hypothyroidism
* Hyperprolactinemia

Primary outcomes:
measure: To compare the rate of ovulation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: HIT Hospital
state: Punjab
Study officials:
affiliation: HITEC-Institute of Medical Sciences
name: Rukhsana Shaheen Afzal, MBBS,FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05886218: Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
Official title: A Before/After Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sugammadex
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2023-06-02
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients scheduled for surgical procedures in the UC Davis Medical Center main ORs will be screened for potential enrollment.

Brief summary: This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.


Eligibility criteria: Inclusion Criteria:

* age greater than 18 years
* scheduled for an elective laparoscopic gastric bypass procedure

Exclusion Criteria:

* age less than 18 years
* pregnancy
* prisoners
* significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
* patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\>98%)

Primary outcomes:
measure: Oxygen desaturation
timeFrame: 24 hours
Secondary outcomes:
measure: The rate of compliance with muscle relaxant monitoring and reversal protocols
timeFrame: 24 hours
measure: Total intraoperative rocuronium use
timeFrame: 24 hours
measure: Total sugammadex dose
timeFrame: 24 hours
measure: Post-operative supplemental oxygen requirement
timeFrame: 24 hours
measure: Post-operative unit length of stay
timeFrame: 7 days
measure: Hospital Length of stay
timeFrame: 7 days
measure: Success rate for wearable device
timeFrame: 24 hours
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: UC Davis Medical Center
state: California
Study officials:
References:
Clinical trial NCT03352518: Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device
Official title: Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: RSP Systems A/S
Sponsor class: INDUSTRY
First posted: 2017-11-24
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

Detailed description: Subjects will collect spectral raman data on device every 15 minutes for 10 hours a day for five days. The five days will be distributes with in a timeframe of ten days. A Flash Glucose Monitor will be used as a comparator. In addition to this, four daily capillary Blood Glucose readings will be collected.

Eligibility criteria: Inclusion Criteria:

* Male and female subjects 18 years of age or older
* Diabetic patients (all types)

Exclusion Criteria:

* Pregnant women
* Subjects not able to understand and read Danish
* In investigator's opinion, subject is not able to follow instructions as specified in the protocol
* Subjects not able to hold hand/arm steadily
* Extensive skin changes, tattoos or diseases on probe application site
* Known allergy to medical grade alcohol used to disinfect skin

Primary outcomes:
measure: Generation and validation of predictive calibration models
timeFrame: 3 months
Secondary outcomes:
measure: Safety assessment of the intervention by the paucity of adverse events
timeFrame: 3 months
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Department of Endocrinology M, Odense University Hospital
Study officials:
affiliation: University Hospital Odense
name: Jan Erik Henriksen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06773013: Safety and Effectiveness of Sonu for Pediatric Nasal Congestion
Official title: Safety and Effectiveness of Sonu Acoustic Resonance Therapy for the Treatment of Pediatric Patients With Moderate to Severe Nasal Congestion.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Nasal Congestion and Inflammations
Lead sponsor: Third Wave Therapeutics
Sponsor class: INDUSTRY
First posted: 2025-01-14
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To demonstrate the safety and effectiveness of Sonu for the treatment of pediatric patients with moderate to severe nasal congestion.


Eligibility criteria: Inclusion Criteria:

* Pediatric subjects between the ages of 12 to 21 years
* Present with symptoms of nasal congestion for 1 month or more prior to treatment
* Have a 24 hour reflective nasal congestion subscore of the TNSS of 2 or more on a 0 to 3 scale at the time of screening

Exclusion Criteria:

* Head, nasal or sinus surgery within 3 months
* Sinus infection diagnosed within the last month, or rhinitis medicamentosa
* Documented history of nasal polyposis or mass
* Pregnancy

Primary outcomes:
measure: Serious adverse events
timeFrame: 2 weeks
measure: Reduction in nasal congestion subscore
timeFrame: 2 weeks
Secondary outcomes:
measure: Adverse events
timeFrame: 2 weeks
measure: Total Nasal Symptom Score (TNSS)
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Portola Valley
country: United States
facility: Crescendo MD
state: California
Study officials:
affiliation: Crescendo MD
name: Alan Greene, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Luong AU, Yong M, Hwang PH, Lin BY, Gopi P, Mohan V, Ma Y, Johnson J, Yen DM, DeMera RS, Bleier BS. Acoustic resonance therapy is safe and effective for the treatment of nasal congestion in rhinitis: A randomized sham-controlled trial. Int Forum Allergy Rhinol. 2024 May;14(5):919-927. doi: 10.1002/alr.23284. Epub 2023 Oct 9.
Clinical trial NCT04204213: The 8 Section Brocade Tai Chi Therapy for Knee Osteoarthritis
Official title: The 8 Section Brocade Tai Chi Therapy in Disease Management Program for Advanced Knee Osteoarthritis Patients: A Community - Based Care Approach
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis, Knee
Tai Chi
Exercise Training
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2019-12-18
Enrollment: 112
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population with knee osteoarthritis.

Brief summary: Tai Chi exercises have increasingly grown in popularity among older adults in the past decades. It has been well studied to its efficacies in proportion with the management of elderly fall prevention and mineral-structured bone density enhancement. Nevertheless, existing study sources do little exemplified a quantifiable measures of effects in patients suffer from osteoarthritis of knees being impacted from a routine performance of Tai Chi.

Detailed description: 112 patients with end stage osteoarthritis knee had enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks. Followup measures were taken at baseline, 3 and 6 months post course commencement using the International Physical Activity Questionnaire (IPAQ), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), SF-36v2 Health Survey and the Client Satisfaction Questionnaire (CSQ-8).

Eligibility criteria: Inclusion Criteria:

1. Diagnosed in symptomatic knee OA of Kellgren Lawrence (KL) grade 3 or 4, and have elected on list waiting for lower limb arthroplasty surgery
2. Aged 55 or above
3. Able to ambulate independently
4. Able to communicate in Cantonese

   Exclusion Criteria:
5. Previously underwent total knee replacement surgery
6. Diagnosed with other non-OA arthritide forms of the knees
7. Unable to complete all four sessions
8. Unable to complete all time-point measurements

Primary outcomes:
measure: Total physical activity metabolic equivalent of task (MET)-minutes per week
timeFrame: 6 Months
Secondary outcomes:
measure: Symptoms and Physical Functional Disability Scores
timeFrame: 6 Months
measure: Client Satisfactory Questionnaires Scores
timeFrame: 6 Months
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Department of Orthopaedics & Traumatology
Study officials:
References:
citation: Ho KK, Pong G, Poon QW, Kwok JY, Chau WW, Ong MT. A community-centric multi-disciplinary education program with the 8-section brocade Tai Chi therapy for patients with osteoarthritis of the knee - a pilot study. BMC Complement Med Ther. 2021 Dec 14;21(1):297. doi: 10.1186/s12906-021-03480-2.
Clinical trial NCT02822313: Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-07-04
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF
* Signed and dated Informed Consent Form
* Signed and dated HIPAA Form
* An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00958113: Autoimmune Thyroid Disease Genetic Study
Official title: Autoimmune Thyroid Disease Genetic Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hashimoto's Disease
Graves' Disease
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2009-08-13
Enrollment: 199
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen in Endocrinology Clinic

Brief summary: The hypothesis of this project is that specific genes can be identified that contribute to genetic susceptibility to autoimmune thyroid disease (AITD) in different populations. The specific aim of this project is carry out one or more genomewide association studies (GWAS) to map and ultimately identify genes that confer susceptibility to AITD. AITD consists principally of Hashimoto's Thyroiditis (HT) and Graves' Disease (GD), characterized clinically generally by hypothyroidism and hyperthyroidism, respectively. Both HT and GD are autoimmune diseases characterized by infiltration of the thyroid by T and B cells that are reactive with thyroid antigens and by the production of thyroid autoantibodies (TAB). While there is some evidence that there may be genes specific to either GD or HT, other genes appear to be common to both, and some genes may furthermore be in common to susceptibility to other autoimmune diseases. Genes known to play a role in AITD include HLA, CTLA4, thyroglobulin (TG), THSR, and CD40, PTPN2, and PTPN22, several of which are also involved in susceptibility to other autoimmune diseases. All of these genes interact in a complex manner that has yet to be understood. Furthermore, it seems clear that relatively few of the genes involved in susceptibility to AITD have thus far been discovered.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of abnormal thyroid function (hypo or hyperthyroidism) due to autoimmune thyroid disease

Exclusion Criteria:

* Lack of documentation of abnormal thyroid function or clear evidence of autoimmune etiology

Primary outcomes:
measure: Map and identify genes that confer susceptibility to Autoimmune Thyroid Disease (AITD)
timeFrame: Approximately one year after all samples are collected
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Denver
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Richard Spritz, MD
role: PRINCIPAL_INVESTIGATOR
References: